Want to see AKBA full AI Analyst Report?
AKBA Stock Chart & Stats
$1.40
$0.30(14.49%)
At close: 4:00 PM EST
$1.40
$0.30(14.49%)
Day’s Range― - ―
52-Week Range$0.82 - $4.04
Previous CloseN/A
Volume5.66M
Average Volume (3M)5.47M
Market Cap
$359.47M
Enterprise Value$424.77
Total Cash (Recent Filing)$162.64M
Total Debt (Recent Filing)$12.49M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Jul 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding268,258,240
10 Day Avg. Volume4,104,800
30 Day Avg. Volume5,472,004
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)12.70
Price to Sales (P/S)1.75
P/FCF Ratio6.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$206.63M
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowSustained positive operating and free cash flow (~$60M TTM) materially improves financial flexibility versus prior years. This durable cash generation supports continued commercialization, funds multiple clinical programs, lowers near-term financing need and underpins operations for the next 2+ years.
Accelerating Vafseo Commercial AdoptionRapid patient and prescriber uptake, rising quarter-over-quarter, indicates durable market penetration. Broader adoption across dialysis providers and high observed-dosing adherence suggest recurring prescription flows, expanding addressable market and more predictable product revenue over the medium term.
Positive VOICE Interim Trial ResultsInterim VOICE data showing superiority on the composite endpoint and fewer hospitalizations is a structural clinical validation. Early positive safety/efficacy signals can materially boost formulary uptake in dialysis centers, payer acceptance, and long-term prescribing trends for Vafseo.
Bears Say
Auryxia Generic-driven Revenue DeclineLoss of Auryxia revenue is structural: authorized generics and new entrants have reduced pricing and volumes. This durable decline shrinks product diversification and increases reliance on Vafseo to drive top-line growth, elevating execution and adoption risk over the medium term.
Ongoing Net Losses And Negative ROEDespite improved operating margins and positive EBIT, persistent net losses and negative ROE indicate earnings instability. Over months this constrains reinvestment, limits shareholder returns, and may force dilutive financing if cash generation slows or trial/commercial costs rise.
Authorized Share Increase Expands Dilution RiskExpanded authorized shares provide financing flexibility but create a credible dilution pathway. Over the medium term this can pressure per-share economics if management raises equity to fund trials or commercialization, affecting investor returns and governance alignment.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.82 and its highest was $4.04 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $359.47M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.002.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.04.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 268,258,240 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went down -20.27%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (257.14% Upside)
$5.00 (257.14% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $62.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA Stock 12 Month Forecast
Average Price Target
$5.00
▲(257.14% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.85% Insiders
8.42% Mutual Funds
0.33% Other Institutional Investors
77.30% Public Companies and
Individual Investors